AstraZeneca COVID-19 vaccine trial delays: A timeline

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by clicking here.

Oct. 1: The FDA says it is widening its examination of the vaccine by taking a look at the outcomes of earlier research studies of other vaccines made by AstraZeneca scientists to see if similar adverse effects emerged in those trials..
Oct. 21: An individual in the Brazil arm of the study passes away, but the drugmaker reveals that the individual got a placebo, not the vaccine. The reason for the research study individuals death is not exposed.

Sept. 9: AstraZeneca announces that it has taken a “voluntary pause” of its stage 3 trial after an unfavorable reaction in a client in the U.K..

AstraZenecas final-stage clinical trial for its COVID-19 vaccine has been postponed in the U.S. for over a month, and theres no public info on when it will resume.

A timeline of occasions because the trial was halted:.

Sept. 15: An official from the National Institutes of Health tells Kaiser Health News that the company is “very concerned” about the postponed AstraZenecas trial..

Sept. 11: Mr. Soriot states the company should know by the end of the year whether its vaccine is efficient and safe..

Sept. 12: AstraZeneca resumes its trial in the U.K. after acquiring approval from the Medicines Health Regulatory Authority..

More posts on pharmacy: Remdesivir becomes very first FDA-approved COVID-19 treatmentConvalescent plasma shows no advantage for COVID-19 patients in clinical trialA breakdown of the 4 COVID-19 vaccine trials in late-stage screening.

Sept. 10: During a teleconference with investors, AstraZeneca CEO Pascal Soriot divulges that the vaccine trial had likewise been halted in July after a participant had neurological symptoms, later associated to numerous sclerosis and not the vaccine. Some experts began criticizing the drugmaker for an absence of transparency..

Sept. 18: A safety report shows that the U.K. woman who had the unfavorable response that halted the trial had actually struggled with transverse myelitis, an unusual neurological condition in which the spinal cable becomes inflamed. Its still not known if the transverse myelitis is connected to AstraZenecas vaccine..

Maia Anderson –
Friday, October 23rd, 2020
Print|Email.